What’s new and exciting in ATTR cardiac amyloidosis in 2024 | Amyloidosis Foundation
Join Dr. Fredrick Ruberg and Dr. Omar Siddiqi as they discuss the general overview of ATTR treatment with new developments over the past…
Join Dr. Fredrick Ruberg and Dr. Omar Siddiqi as they discuss the general overview of ATTR treatment with new developments over the past…
The standard treatment paradigm for muscle invasive bladder cancer has been neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. However, efforts are ongoing to personalize treatment…
Eliezer Van Allen, MD, discusses immuno-oncology in relation to precision cancer medicine.
The phase 3 KEYNOTE-B21 study missed its primary end point, as pembrolizumab plus chemotherapy did not improve disease-free survival in newly diagnosed, high-risk endometrial cancer.
Ashwin Kishtagari, MD, discusses the treatment of patients with myelofibrosis following progression on ruxolitinib.
Tumor-infiltrating B lymphocytes were associated with worse outcomes in patients with metastatic ccRCC treated with axitinib plus anti–PD-1 therapy.
An abstract is unavailable.
Petros Grivas, MD, PhD, expands on key updates in the second-line management of urothelial cancer.
AbstractBackground:. Distinguishing ovarian cancer from other gynecological malignancies is crucial for patient survival yet hindered by non-specific symptoms and limited understanding of ovarian cancer pathogenesis.…
Hideho Okada, MD, PhD, discusses cancer immunoprevention through the lens of vaccine approaches in patients with low-grade glioma.
An abstract is unavailable.